FibroGen Company Profile (NASDAQ:FGEN)

About FibroGen (NASDAQ:FGEN)

FibroGen logoFibroGen, Inc. is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200. FG-4592 is an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylases (HIF-PHs), which acts by stimulating the body's natural pathway of erythropoiesis or red blood cell production. FG-4592 is in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD). FG-3019 is a monoclonal antibody, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, Duchenne muscular dystrophy (DMD) and liver fibrosis. FG-6874 is in Phase I clinical trials, and FG-5200 is a corneal implant medical device, which is in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:FGEN
  • CUSIP: N/A
  • Web: www.fibrogen.com
Capitalization:
  • Market Cap: $2.48 billion
  • Outstanding Shares: 69,944,000
Average Prices:
  • 50 Day Moving Avg: $32.24
  • 200 Day Moving Avg: $27.21
  • 52 Week Range: $15.60 - $35.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -53.79
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $178.19 million
  • Price / Sales: 13.93
  • Book Value: $2.04 per share
  • Price / Book: 17.40
Profitability:
  • EBIDTA: ($52,180,000.00)
  • Net Margins: -37.60%
  • Return on Equity: -36.41%
  • Return on Assets: -14.13%
Debt:
  • Debt-to-Equity Ratio: 0.65%
  • Current Ratio: 4.27%
  • Quick Ratio: 4.27%
Misc:
  • Average Volume: 460,752 shs.
  • Beta: 1.77
  • Short Ratio: 4.76
 
Frequently Asked Questions for FibroGen (NASDAQ:FGEN)

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

How were FibroGen's earnings last quarter?

FibroGen, Inc (NASDAQ:FGEN) announced its earnings results on Tuesday, May, 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.11. The firm earned $26.89 million during the quarter, compared to analyst estimates of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. View FibroGen's Earnings History.

Where is FibroGen's stock going? Where will FibroGen's stock price be in 2017?

8 brokerages have issued 12 month target prices for FibroGen's stock. Their predictions range from $31.00 to $52.00. On average, they expect FibroGen's share price to reach $42.67 in the next year. View Analyst Ratings for FibroGen.

Who are some of FibroGen's key competitors?

Who are FibroGen's key executives?

FibroGen's management team includes the folowing people:

  • Thomas B. Neff, Chairman of the Board, Chief Executive Officer, Founder
  • Pat Cotroneo, Chief Financial Officer, Vice President - Finance
  • Frank H. Valone M.D., Senior Fellow, Clinical Development
  • K. Peony Yu M.D., Chief Medical Officer
  • Jeffrey L. Edwards, Independent Director
  • Jeffrey William Henderson, Independent Director
  • Thomas F. Kearns Jr., Independent Director
  • Kalevi Kurkijarvi Ph.D., Independent Director
  • Rory B. Riggs, Independent Director

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering (IPO) on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

Who owns FibroGen stock?

FibroGen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include ECOR1 CAPITAL, LLC Total Shares: 1,322,991 (1.90%), Omega Fund Management LLC (0.90%), Handelsbanken Fonder AB (0.34%), Boston Advisors LLC (0.25%), Strs Ohio (0.20%) and Acadian Asset Management LLC (0.11%). Company insiders that own FibroGen stock include Frank H Md Valone, K Peony Yu, Kalevi Kurkijarvi, Miguel Madero, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr, Thomas F Kearns, Jr and Toshinari Tamura. View Institutional Ownership Trends for FibroGen.

Who sold FibroGen stock? Who is selling FibroGen stock?

FibroGen's stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC, Acadian Asset Management LLC and Capital Impact Advisors LLC. Company insiders that have sold FibroGen stock in the last year include K Peony Yu, Kalevi Kurkijarvi, Pat Cotroneo, Rory B Riggs, Thomas B Neff, Thomas F Kearns Jr and Toshinari Tamura. View Insider Buying and Selling for FibroGen.

Who bought FibroGen stock? Who is buying FibroGen stock?

FibroGen's stock was acquired by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Handelsinvest Investeringsforvaltning, Russell Investments Group Ltd. and Strs Ohio. View Insider Buying and Selling for FibroGen.

How do I buy FibroGen stock?

Shares of FibroGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is FibroGen's stock price today?

One share of FibroGen stock can currently be purchased for approximately $35.50.


MarketBeat Community Rating for FibroGen (NASDAQ FGEN)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  94 (Vote Outperform)
Underperform Votes:  46 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about FibroGen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for FibroGen (NASDAQ:FGEN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $42.67 (20.19% upside)

Analysts' Ratings History for FibroGen (NASDAQ:FGEN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/21/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$31.00MediumView Rating Details
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$50.00HighView Rating Details
6/26/2017Citigroup Inc.Reiterated RatingBuy$48.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformMediumView Rating Details
6/22/2017Stifel NicolausReiterated RatingBuy$32.00 -> $38.00LowView Rating Details
1/18/2017Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
11/9/2016Leerink SwannReiterated RatingBuy$52.00N/AView Rating Details
8/9/2016Credit Suisse GroupReiterated RatingBuy$37.00N/AView Rating Details
9/23/2015Lake Street CapitalInitiated CoverageHold$25.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for FibroGen (NASDAQ:FGEN)
Earnings by Quarter for FibroGen (NASDAQ:FGEN)
Earnings History by Quarter for FibroGen (NASDAQ FGEN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.63)($0.52)$26.02 million$26.89 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.53)($0.54)$19.29 million$31.91 millionViewListenView Earnings Details
11/8/2016Q3($0.63)($0.38)$24.30 million$30.10 millionViewListenView Earnings Details
8/8/2016Q2$0.36$0.35$80.58 million$89.28 millionViewListenView Earnings Details
5/9/2016Q116($0.56)($0.45)$16.89 million$28.28 millionViewListenView Earnings Details
2/29/2016Q4($0.54)($0.85)$40.44 million$24.44 millionViewListenView Earnings Details
11/12/2015Q3($0.61)($0.74)$28.74 million$19.54 millionViewListenView Earnings Details
8/13/2015Q215$0.73$0.83$111.75 million$120.55 millionViewListenView Earnings Details
5/12/2015Q115($0.53)($0.78)$34.00 million$16.30 millionViewN/AView Earnings Details
3/26/2015Q414($0.90)($0.82)$16.49 million$16.11 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for FibroGen (NASDAQ:FGEN)
2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.77)($0.48)($0.63)
Q2 20173($0.47)($0.43)($0.45)
Q3 20173($0.46)($0.22)($0.37)
Q4 20173($0.58)($0.45)($0.52)
Q1 20181($0.87)($0.87)($0.87)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181$0.77$0.77$0.77
Q4 20181($0.76)($0.76)($0.76)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for FibroGen (NASDAQ:FGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for FibroGen (NASDAQ:FGEN)
Insider Ownership Percentage: 14.90%
Institutional Ownership Percentage: 43.87%
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Institutional Ownership by Quarter for FibroGen (NASDAQ:FGEN)
Insider Trades by Quarter for FibroGen (NASDAQ:FGEN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Thomas B NeffCEOSell38,636$35.09$1,355,737.24View SEC Filing  
7/24/2017Thomas B NeffCEOSell18,900$35.06$662,634.00View SEC Filing  
7/17/2017Kalevi KurkijarviDirectorSell2,000$33.45$66,900.00View SEC Filing  
7/10/2017K Peony YuInsiderSell5,000$32.98$164,900.00View SEC Filing  
7/7/2017Thomas B NeffCEOSell38,636$33.38$1,289,669.68View SEC Filing  
7/6/2017Pat CotroneoVPSell4,000$34.00$136,000.00View SEC Filing  
7/6/2017Thomas B NeffCEOSell18,900$33.53$633,717.00View SEC Filing  
6/22/2017Pat CotroneoVPSell3,000$32.00$96,000.00View SEC Filing  
6/22/2017Thomas B NeffCEOSell38,636$31.52$1,217,806.72View SEC Filing  
6/19/2017Pat CotroneoVPSell5,500$30.00$165,000.00View SEC Filing  
6/16/2017Thomas B NeffCEOSell38,636$29.40$1,135,898.40View SEC Filing  
6/15/2017Kalevi KurkijarviDirectorSell2,000$28.50$57,000.00View SEC Filing  
6/14/2017K Peony YuInsiderSell3,721$28.95$107,722.95View SEC Filing  
6/12/2017Pat CotroneoVPSell2,891$28.75$83,116.25View SEC Filing  
6/12/2017Toshinari TamuraDirectorSell30,000$28.89$866,700.00View SEC Filing  
6/6/2017Thomas F Kearns JrDirectorSell18,000$28.71$516,780.00View SEC Filing  
5/31/2017Thomas B NeffCEOSell38,636$26.21$1,012,649.56View SEC Filing  
5/16/2017Kalevi KurkijarviDirectorSell2,000$27.40$54,800.00View SEC Filing  
5/16/2017Thomas B NeffCEOSell38,636$27.70$1,070,217.20View SEC Filing  
5/15/2017Thomas B NeffCEOSell18,900$27.75$524,475.00View SEC Filing  
5/10/2017K Peony YuInsiderSell5,000$26.38$131,900.00View SEC Filing  
4/25/2017K Peony YuInsiderSell5,000$28.00$140,000.00View SEC Filing  
4/25/2017Pat CotroneoVPSell6,500$28.00$182,000.00View SEC Filing  
4/25/2017Thomas B NeffCEOSell38,636$26.92$1,040,081.12View SEC Filing  
4/24/2017Thomas B NeffCEOSell18,900$26.35$498,015.00View SEC Filing  
4/17/2017Kalevi KurkijarviDirectorSell2,000$25.25$50,500.00View SEC Filing  
4/13/2017Thomas B NeffCEOSell38,636$24.79$957,786.44View SEC Filing  
4/4/2017Thomas B NeffCEOSell38,636$23.92$924,173.12View SEC Filing  
3/21/2017Thomas B NeffCEOSell38,636$24.34$940,400.24View SEC Filing  
3/20/2017Thomas B NeffCEOSell18,900$24.88$470,232.00View SEC Filing  
3/15/2017Thomas B NeffCEOSell38,636$25.07$968,604.52View SEC Filing  
2/16/2017Kalevi KurkijarviDirectorSell2,000$24.45$48,900.00View SEC Filing  
2/14/2017Thomas B NeffCEOSell38,636$23.94$924,945.84View SEC Filing  
2/13/2017Thomas B NeffCEOSell18,900$23.97$453,033.00View SEC Filing  
2/9/2017Thomas B NeffCEOSell37,798$23.46$886,741.08View SEC Filing  
1/27/2017Thomas B NeffCEOSell37,798$23.29$880,315.42View SEC Filing  
1/19/2017Kalevi KurkijarviDirectorSell2,000$24.90$49,800.00View SEC Filing  
1/12/2017Thomas B NeffCEOSell37,798$23.85$901,482.30View SEC Filing  
1/11/2017Pat CotroneoVPSell6,500$24.00$156,000.00View SEC Filing  
1/10/2017K Peony YuInsiderSell5,000$23.56$117,800.00View SEC Filing  
12/28/2016Thomas B NeffCEOSell37,798$20.74$783,930.52View SEC Filing  
12/16/2016Rory B RiggsDirectorSell20,000$20.87$417,400.00View SEC Filing  
12/13/2016Thomas B NeffCEOSell37,798$21.24$802,829.52View SEC Filing  
12/12/2016Pat CotroneoVPSell2,344$22.05$51,685.20View SEC Filing  
12/12/2016Thomas B NeffCEOSell18,899$21.48$405,950.52View SEC Filing  
11/29/2016Thomas B NeffCEOSell37,798$22.80$861,794.40View SEC Filing  
11/28/2016Thomas B NeffCEOSell18,899$22.74$429,763.26View SEC Filing  
11/18/2016Thomas F Kearns JrDirectorSell18,000$22.40$403,200.00View SEC Filing  
11/17/2016Thomas B NeffCEOSell37,798$22.29$842,517.42View SEC Filing  
11/1/2016Thomas B NeffCEOSell37,798$16.76$633,494.48View SEC Filing  
10/19/2016Thomas B NeffCEOSell37,798$17.75$670,914.50View SEC Filing  
10/18/2016Thomas B NeffCEOSell18,899$17.94$339,048.06View SEC Filing  
10/4/2016Thomas B NeffCEOSell18,899$20.67$390,642.33View SEC Filing  
10/3/2016Thomas B NeffCEOSell18,899$20.55$388,374.45View SEC Filing  
9/21/2016Thomas B NeffCEOSell37,798$21.66$818,704.68View SEC Filing  
9/14/2016K Peony YuInsiderSell2,345$18.66$43,757.70View SEC Filing  
9/12/2016Pat CotroneoVPSell2,345$18.22$42,725.90View SEC Filing  
9/9/2016Thomas B NeffCEOSell37,798$18.99$717,784.02View SEC Filing  
8/26/2016Thomas B NeffCEOSell37,798$17.80$672,804.40View SEC Filing  
7/27/2016Thomas B NeffCEOSell37,798$18.38$694,727.24View SEC Filing  
7/13/2016Thomas B NeffCEOSell27,000$17.50$472,500.00View SEC Filing  
6/29/2016Thomas B NeffCEOSell27,000$16.02$432,540.00View SEC Filing  
6/15/2016Pat CotroneoCFOSell1,796$16.49$29,616.04View SEC Filing  
6/15/2016Thomas B NeffCEOSell27,000$16.48$444,960.00View SEC Filing  
6/10/2016K Peony YuInsiderSell2,344$17.96$42,098.24View SEC Filing  
6/3/2016Thomas B NeffCEOSell27,000$18.99$512,730.00View SEC Filing  
5/20/2016Thomas B NeffCEOSell27,000$17.68$477,360.00View SEC Filing  
5/16/2016Pat CotroneoCFOSell6,107$17.60$107,483.20View SEC Filing  
5/3/2016Thomas B NeffCEOSell27,000$17.78$480,060.00View SEC Filing  
4/20/2016Thomas B NeffCEOSell27,000$19.98$539,460.00View SEC Filing  
4/19/2016Thomas B NeffCEOSell13,500$20.21$272,835.00View SEC Filing  
4/5/2016Thomas B NeffCEOSell27,000$21.11$569,970.00View SEC Filing  
4/1/2016Frank H Md ValoneInsiderSell10,750$21.11$226,932.50View SEC Filing  
3/22/2016Thomas B NeffCEOSell27,000$18.74$505,980.00View SEC Filing  
3/8/2016Thomas B NeffCEOSell27,000$19.62$529,740.00View SEC Filing  
3/1/2016Frank H Md ValoneInsiderSell10,750$16.84$181,030.00View SEC Filing  
2/23/2016Thomas B NeffCEOSell27,000$19.11$515,970.00View SEC Filing  
2/22/2016Thomas B NeffCEOSell13,500$19.81$267,435.00View SEC Filing  
2/16/2016Frank H. Md ValoneinsiderSell10,750$18.41$197,907.50View SEC Filing  
2/10/2016Thomas B. NeffCEOSell27,000$15.31$413,370.00View SEC Filing  
1/29/2016Thomas B. NeffCEOSell27,000$19.41$524,070.00View SEC Filing  
1/21/2016Thomas F Kearns JrDirectorSell1,572$22.08$34,709.76View SEC Filing  
1/14/2016Thomas B. NeffCEOSell27,000$23.69$639,630.00View SEC Filing  
12/24/2015Thomas F. Kearns, Jr.DirectorSell7,800$30.88$240,864.00View SEC Filing  
12/23/2015Thomas B. NeffCEOSell27,000$30.10$812,700.00View SEC Filing  
12/11/2015Thomas B. NeffCEOSell27,000$29.59$798,930.00View SEC Filing  
12/10/2015K Peony YuVPSell1,093$28.96$31,653.28View SEC Filing  
12/8/2015Miguel MaderoDirectorSell40,386$30.49$1,231,369.14View SEC Filing  
11/30/2015K Peony YuVPSell5,000$30.00$150,000.00View SEC Filing  
11/25/2015Pat CotroneoCFOSell5,000$30.00$150,000.00View SEC Filing  
11/24/2015Thomas B. NeffCEOSell13,500$28.98$391,230.00View SEC Filing  
11/24/2015Thomas F. Kearns, Jr.DirectorSell3,900$29.00$113,100.00View SEC Filing  
11/23/2015Thomas B. NeffCEOSell13,500$27.99$377,865.00View SEC Filing  
11/23/2015Thomas F. Kearns, Jr.DirectorSell3,900$28.02$109,278.00View SEC Filing  
11/17/2015K Peony YuVPSell5,000$28.00$140,000.00View SEC Filing  
11/10/2015K Peony YuVPSell5,000$25.62$128,100.00View SEC Filing  
11/9/2015K Peony YuVPSell2,500$25.00$62,500.00View SEC Filing  
11/2/2015Frank H. Md ValoneinsiderSell10,000$23.18$231,800.00View SEC Filing  
10/30/2015Thomas B. NeffCEOSell27,000$24.06$649,620.00View SEC Filing  
10/21/2015Thomas F. Kearns, Jr.DirectorSell7,800$23.83$185,874.00View SEC Filing  
10/19/2015Frank H. Md ValoneinsiderSell10,000$23.00$230,000.00View SEC Filing  
10/19/2015K Peony YuVPSell5,000$24.00$120,000.00View SEC Filing  
10/16/2015K Peony YuVPSell5,000$21.46$107,300.00View SEC Filing  
10/16/2015Thomas B. NeffCEOSell27,000$21.86$590,220.00View SEC Filing  
10/2/2015Thomas B. NeffCEOSell27,000$21.59$582,930.00View SEC Filing  
10/1/2015Frank H. Md ValoneinsiderSell10,000$21.38$213,800.00View SEC Filing  
9/18/2015Thomas B. NeffCEOSell27,000$29.10$785,700.00View SEC Filing  
9/15/2015Pat CotroneoCFOSell1,093$27.95$30,549.35View SEC Filing  
9/14/2015Rory B. RiggsDirectorSell50,000$27.61$1,380,500.00View SEC Filing  
9/11/2015Miguel MaderoDirectorSell20,600$27.66$569,796.00View SEC Filing  
9/10/2015K Peony YuVPSell1,093$27.84$30,429.12View SEC Filing  
9/10/2015Pat CotroneoCFOSell7,500$27.33$204,975.00View SEC Filing  
9/4/2015Thomas B. NeffCEOSell13,500$22.88$308,880.00View SEC Filing  
9/3/2015Thomas B. NeffCEOSell13,500$22.92$309,420.00View SEC Filing  
9/1/2015Frank H. Md ValoneinsiderSell10,000$23.58$235,800.00View SEC Filing  
7/23/2015Thomas B NeffCEOSell27,000$24.71$667,170.00View SEC Filing  
7/20/2015Frank H Md ValoneInsiderSell1,000$23.70$23,700.00View SEC Filing  
7/20/2015Pat CotroneoCFOSell7,881$23.47$184,967.07View SEC Filing  
7/9/2015Thomas B NeffCEOSell27,000$22.11$596,970.00View SEC Filing  
7/6/2015K Peony YuVPSell5,381$22.69$122,094.89View SEC Filing  
6/25/2015Thomas B NeffCEOSell27,000$23.57$636,390.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for FibroGen (NASDAQ:FGEN)
Latest Headlines for FibroGen (NASDAQ:FGEN)
Source:
DateHeadline
americanbankingnews.com logoFibroGen, Inc (NASDAQ:FGEN) CEO Sells $662,634.00 in Stock
www.americanbankingnews.com - July 26 at 7:58 PM
americanbankingnews.com logoThomas B. Neff Sells 38,636 Shares of FibroGen, Inc (NASDAQ:FGEN) Stock
www.americanbankingnews.com - July 26 at 7:17 PM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Lowers FibroGen, Inc (NASDAQ:FGEN) to Neutral
www.americanbankingnews.com - July 22 at 7:34 PM
prnewswire.com logoCongress Could Have Major Impact on Biotech Companies - PR Newswire (press release)
www.prnewswire.com - July 21 at 10:03 PM
thestreet.com logoTeligent Shares Rise on FDA Approval for Erythromycin Topical Gel ... - TheStreet.com
www.thestreet.com - July 21 at 10:03 PM
americanbankingnews.com logoFibroGen, Inc (NASDAQ:FGEN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - July 21 at 11:43 AM
thestreet.com logoBiotech Movers: Vertex Continues to Move on Data for CF Regimen - TheStreet.com
www.thestreet.com - July 20 at 4:17 PM
americanbankingnews.com logo$34.80 Million in Sales Expected for FibroGen, Inc (FGEN) This Quarter
www.americanbankingnews.com - July 19 at 4:54 PM
americanbankingnews.com logoContrasting Adamas Pharmaceuticals (ADMS) and FibroGen (NASDAQ:FGEN)
www.americanbankingnews.com - July 19 at 8:51 AM
americanbankingnews.com logoFibroGen, Inc (NASDAQ:FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares
www.americanbankingnews.com - July 18 at 7:52 PM
americanbankingnews.com logoZacks: Brokerages Expect FibroGen, Inc (NASDAQ:FGEN) Will Post Earnings of -$0.47 Per Share
www.americanbankingnews.com - July 17 at 10:49 AM
americanbankingnews.com logoBrokers Issue Forecasts for FibroGen, Inc's Q2 2017 Earnings (NASDAQ:FGEN)
www.americanbankingnews.com - July 13 at 10:50 AM
americanbankingnews.com logoFibroGen, Inc (FGEN) Insider Sells $164,900.00 in Stock
www.americanbankingnews.com - July 11 at 10:52 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) Coverage Initiated by Analysts at Jefferies Group LLC
www.americanbankingnews.com - July 10 at 5:26 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) VP Sells $136,000.00 in Stock
www.americanbankingnews.com - July 7 at 8:41 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) CEO Thomas B. Neff Sells 18,900 Shares
www.americanbankingnews.com - July 7 at 8:16 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) to Post Q2 2017 Earnings of ($0.45) Per Share, William Blair Forecasts
www.americanbankingnews.com - June 28 at 7:32 AM
americanbankingnews.com logoFibroGen, Inc (FGEN) Given Buy Rating at Citigroup Inc.
www.americanbankingnews.com - June 26 at 5:50 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 26 at 10:53 AM
americanbankingnews.com logoFibroGen, Inc (FGEN) Rating Reiterated by William Blair
www.americanbankingnews.com - June 26 at 8:16 AM
americanbankingnews.com logoFibroGen, Inc (FGEN) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - June 24 at 7:20 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) VP Pat Cotroneo Sells 3,000 Shares
www.americanbankingnews.com - June 23 at 7:32 PM
americanbankingnews.com logoInsider Selling: FibroGen, Inc (FGEN) CEO Sells 38,636 Shares of Stock
www.americanbankingnews.com - June 23 at 7:15 PM
americanbankingnews.com logo Analysts Expect FibroGen, Inc (FGEN) Will Announce Quarterly Sales of $34.74 Million
www.americanbankingnews.com - June 23 at 6:58 PM
americanbankingnews.com logoStifel Nicolaus Reiterates Buy Rating for FibroGen, Inc (FGEN)
www.americanbankingnews.com - June 22 at 8:34 PM
nasdaq.com logoFibroGen's Pamrevlumab Gets Orphan Drug Designation To Treat Pancreatic Cancer - Nasdaq
www.nasdaq.com - June 22 at 9:46 AM
finance.yahoo.com logoFibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
finance.yahoo.com - June 22 at 9:46 AM
americanbankingnews.com logoFibroGen, Inc (FGEN) VP Sells $165,000.00 in Stock
www.americanbankingnews.com - June 21 at 8:05 PM
americanbankingnews.com logo Analysts Expect FibroGen, Inc (FGEN) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - June 21 at 7:46 AM
americanbankingnews.com logoInsider Selling: FibroGen, Inc (FGEN) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - June 19 at 7:57 PM
americanbankingnews.com logoFibroGen, Inc (FGEN) Insider K Peony Yu Sells 3,721 Shares
www.americanbankingnews.com - June 16 at 7:58 PM
americanbankingnews.com logoPat Cotroneo Sells 2,891 Shares of FibroGen Inc (FGEN) Stock
www.americanbankingnews.com - June 14 at 8:19 PM
americanbankingnews.com logoToshinari Tamura Sells 30,000 Shares of FibroGen, Inc (FGEN) Stock
www.americanbankingnews.com - June 14 at 7:44 AM
feeds.benzinga.com logoAbout FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
feeds.benzinga.com - June 13 at 7:23 AM
americanbankingnews.com logoInsider Selling: FibroGen Inc (FGEN) Director Sells 18,000 Shares of Stock
www.americanbankingnews.com - June 8 at 10:30 PM
streetinsider.com logoFibroGen (FGEN) Announces European Patent Office Decision to Maintain Patent Relating to Hypoxia-Inducible Factor ... - StreetInsider.com
www.streetinsider.com - June 5 at 11:15 AM
finance.yahoo.com logoEuropean Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
finance.yahoo.com - June 5 at 11:14 AM
finance.yahoo.com logoFibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : June 2, 2017
finance.yahoo.com - June 2 at 6:31 PM
finance.yahoo.com logoETFs with exposure to FibroGen, Inc. : June 2, 2017
finance.yahoo.com - June 2 at 6:31 PM
americanbankingnews.com logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 38,636 Shares of Stock
www.americanbankingnews.com - June 1 at 10:34 PM
americanbankingnews.com logo$34.74 Million in Sales Expected for FibroGen Inc (FGEN) This Quarter
www.americanbankingnews.com - May 27 at 7:33 AM
americanbankingnews.com logoZacks: Brokerages Anticipate FibroGen Inc (FGEN) Will Announce Earnings of -$0.48 Per Share
www.americanbankingnews.com - May 26 at 12:30 AM
finance.yahoo.com logoETFs with exposure to FibroGen, Inc. : May 22, 2017
finance.yahoo.com - May 22 at 4:50 PM
finance.yahoo.com logoFibroGen, Inc. :FGEN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 19, 2017
finance.yahoo.com - May 19 at 4:56 PM
americanbankingnews.com logoFibroGen Inc (FGEN) Director Kalevi Kurkijarvi Sells 2,000 Shares
www.americanbankingnews.com - May 17 at 11:15 PM
americanbankingnews.com logoInsider Selling: FibroGen Inc (FGEN) CEO Sells 18,900 Shares of Stock
www.americanbankingnews.com - May 17 at 10:51 PM
americanbankingnews.com logoFibroGen Inc (FGEN) CEO Thomas B. Neff Sells 38,636 Shares
www.americanbankingnews.com - May 17 at 10:28 PM
finance.yahoo.com logoAkebia Secures Exclusive Access to U.S. Dialysis Patients With Vifor-Fresenius Pact
finance.yahoo.com - May 15 at 4:50 PM
americanbankingnews.com logoInsider Selling: FibroGen Inc (FGEN) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - May 12 at 8:01 PM
americanbankingnews.com logoEquities Analysts Offer Predictions for FibroGen Inc's FY2017 Earnings (FGEN)
www.americanbankingnews.com - May 12 at 12:54 PM

Social

Chart

FibroGen (FGEN) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff